SABS

SAB Biotherapeutics, Inc. (SABS) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing human polyclonal immunotherapeutic antibodies. The company's lead candidate, SAB-142, is a human anti-thymocyte globulin (ATG) designed to prevent or delay the progression of Type 1 Diabetes (T1D). The company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Revenue dropped to zero for the three and six months ended June 30, 2025, compared to $0.26 million and $1.21 million in the prior year periods. This decrease is attributed to the termination of the JPEO Rapid Response Contract and the satisfaction of all obligations under prior US Department of Defense grants by December 31, 2024.
• Operating Expenses:
  • R&D: Increased slightly by 2.6% ($0.2 million) in Q2 2025 compared to Q2 2024, driven by higher salaries and clinical trial costs, offset by reductions in outside lab services and supplies. YTD R&D expenses decreased slightly by 0.8%.
  • G&A: Decreased by 24.9% in Q2 2025 and 27.2% YTD 2025 compared to the prior year, primarily due to reductions in salaries, insurance costs, and administrative support fees.
• Non-Operating Income: The company recognized a gain of $4.41 million YTD 2025 from changes in the fair value of warrant liabilities, compared to $7.69 million in the prior year. This volatility is driven by changes in the fair value of Public and Preferred Warrants.
• Liquidity: Cash and cash equivalents decreased by $5.2 million YTD 2025. Total current liabilities increased to $10.68 million from $7.98 million at year-end 2024, largely due to increases in accrued expenses and operating lease liabilities.

Guidance, Outlook, and Risks

• Capital Raise (Subsequent Event): On July 21, 2025, the company entered into a securities purchase agreement for a Series B Offering, generating approximately $175 million in gross proceeds. This funding is intended to support the Phase 2b SAFEGUARD study of SAB-142 and general corporate purposes.
• Outlook: Management anticipates continued losses as the company advances SAB-142 through clinical trials. Based on current operating expenses and the recent capital raise, the company expects sufficient resources to cover operating cash needs for at least the next twelve months.
• Risks:
  • Dilution: The Series B Preferred Stock is convertible into 100 million shares of common stock (subject to stockholder approval), representing a potential 2,690% increase in outstanding shares as of June 30, 2025.
  • Regulatory & Clinical: Success depends on the outcome of the Phase 2b SAFEGUARD study and future regulatory approvals.
  • Warrant Liability: Significant volatility in net income/loss is driven by the fair value adjustments of warrant liabilities.

Investor Verification Checklist

• Series B Offering Terms: Verify the specific conversion price ($1.75 per share) and the timeline for the required stockholder approval to convert Series B Preferred Stock to common stock.
• Cash Runway: Confirm the burn rate post-capital raise and the specific timeline for the Phase 2b SAFEGUARD study enrollment and data readout.
• Warrant Liability Exposure: Review the fair value assumptions (volatility, risk-free rate) used to value the $1.98 million warrant liability, as changes here significantly impact reported net loss.
• Revenue Pipeline: Assess the likelihood of securing new government grants or commercial partnerships given the cessation of prior grant revenue.
• Board Composition: Note the agreement to nominate up to two individuals designated by RA Capital Healthcare Fund to the Board of Directors.